In more detail, the insulin degrading enzyme (IDE) is imperative during clearance of Aβ peptide fragments and has been recently designated as a prime target for therapeutic treatments against both AD and T2D, respectively114–116. The gene discussed is IDE; the disease is Alzheimer disease.